ID
DB00194|APRD00333|EXPT02753|
描述
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the vaccinia VIRUS and varicella zoster virus.
组
approved,investigational,
指示
For treatment of chickenpox - varicella, herpes zoster and herpes simplex
药效学
Vidarabine is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV). The inhibitory activity of Vidarabine is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts Vidarabine into Vidarabine monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In vitro, Vidarabine triphosphate stops the DNA replication of herpes virus by being incorporated into the DNA strand and preventing the formation of phosphodiester bridges between bases. This ultimately leads to destabilization of the viral DNA strands.
作用机制
Vidarabine stops replication of herpes viral DNA in 2 ways: 1) competitive inhibition of viral DNA polymerase, and consequently 2) incorporation into and termination of the growing viral DNA chain.
Vidarabine is sequentially phosphorylated by kinases to the triphosphate ara-ATP, which is the active form of vidarabine that acts as both an inhibitor and a substrate of viral DNA polymerase. By acting as a substrate for viral DNA polymerase, ara-ATP competitively inhibits dATP leading to the formation of ‘faulty’ DNA. Ara-ATP can also be incorporated into the DNA strand to replace many of the adenosine bases, resulting in the disruption of DNA synthesis.
毒性
Acute massive overdosage by oral ingestion of the ophthalmic ointment has not occurred. However, the rapid deamination to arabinosylhypoxanthine should preclude any difficulty. The oral LD50 for vidarabine is greater than 5020 mg/kg in mice and rats. No untoward effects should result from ingestion of the entire contents of the tube. Overdosage by ocular instillation is unlikely because any excess should be quickly expelled from the conjunctival sac.
代谢
In laboratory animals, vidarabine is rapidly deaminated in the gastrointestinal tract to Ara-Hx.
吸收
Systemetic absorption of vidarabine should not be expected to occur following ocular administration and swallowing lacrimal secretions.
分类
description:This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.
direct-parent:Purine nucleosides
kingdom:Organic compounds
superclass:Nucleosides, nucleotides, and analogues
class:Purine nucleosides
subclass:
alternative-parent:6-aminopurines
alternative-parent:Aminopyrimidines and derivatives
alternative-parent:Azacyclic compounds
alternative-parent:Glycosylamines
alternative-parent:Heteroaromatic compounds
alternative-parent:Hydrocarbon derivatives
alternative-parent:Imidolactams
alternative-parent:N-substituted imidazoles
alternative-parent:Organopnictogen compounds
alternative-parent:Oxacyclic compounds
alternative-parent:Pentoses
alternative-parent:Primary alcohols
alternative-parent:Primary amines
alternative-parent:Secondary alcohols
alternative-parent:Tetrahydrofurans
substituent:6-aminopurine
substituent:Alcohol
substituent:Amine
substituent:Aminopyrimidine
substituent:Aromatic heteropolycyclic compound
substituent:Azacycle
substituent:Azole
substituent:Glycosyl compound
substituent:Heteroaromatic compound
substituent:Hydrocarbon derivative
substituent:Imidazole
substituent:Imidazopyrimidine
substituent:Imidolactam
substituent:Monosaccharide
substituent:N-glycosyl compound
substituent:N-substituted imidazole
substituent:Organic nitrogen compound
substituent:Organic oxygen compound
substituent:Organoheterocyclic compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Oxacycle
substituent:Pentose monosaccharide
substituent:Primary alcohol
substituent:Primary amine
substituent:Purine
substituent:Purine nucleoside
substituent:Pyrimidine
substituent:Secondary alcohol
substituent:Tetrahydrofuran
种类
Anti-Infective Agents
D000890
Antiinfectives for Systemic Use
Antimetabolites
D000963
Antiviral Agents
D000998
Antivirals for Systemic Use
Arabinonucleosides
D001087
Carbohydrates
D002241
Direct Acting Antivirals
Glycosides
D006027
Heterocyclic Compounds, Fused-Ring
D000072471
Noxae
D009676
Nucleic Acids, Nucleotides, and Nucleosides
D009706
Nucleosides
D009705
Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors
Ophthalmologicals
Purine Nucleosides
D011684
Purines
D011687
Ribonucleosides
D012263
Sensory Organs
Toxic Actions
D004786
同义词
language:english; code:; name;9-beta-D-arabinofuranosyl-9H-purin-6-amine
language:english; code:; name;9-beta-D-arabinofuranosyl-adenine
language:english; code:; name;9-beta-D-Arabinofuranosyladenine
language:english; code:; name;9-β-D-arabinofuranosyl-9H-purin-6-amine
language:english; code:; name;9-β-D-arabinofuranosyladenine
language:english; code:; name;Spongoadenosine
language:english; code:inn; name;Vidarabine
language:latin; code:inn; name;Vidarabinum
产品
name:Vira-A
labeller:Monarch Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:61570-367
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1976-11-26
ended-marketing-on:2001-12-07
dosage-form:Ointment
strength:30 mg/1g
route:Topical
fda-application-number:NDA050486
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
混合物
name:Vira-A
ingredients:Vidarabine
name:Medisca Inc.
url:http://www.medisca.com
name:Professional Co.
url:
generic:否; url:; name;Parkedale pharmaceuticals inc
价格
Vidarabine powder
366.59(单位：USD）
g
Vidarabine monohydrate powder
687.0(单位：USD）
g
受影响的生物体
Human Herpes Virus
剂量
form:Ointment
route:Topical
strength:30 mg/1g
atc代码
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
DIRECT ACTING ANTIVIRALS
ANTIVIRALS FOR SYSTEMIC USE
ANTIINFECTIVES FOR SYSTEMIC USE
Antivirals
ANTIINFECTIVES
OPHTHALMOLOGICALS
SENSORY ORGANS
化学品安全技术说明书
//s3-us-west-2.amazonaws.com/drugbank/msds/DB00194.pdf?1265922751
药物相互作用
DB00437The metabolism of Allopurinol can be decreased when combined with Vidarabine.
resource：ChEBI
identifier：45327
resource：PubChem Compound
identifier：21704
resource：PubChem Substance
identifier：46506630
resource：KEGG Compound
identifier：C07195
resource：KEGG Drug
identifier：D00406
resource：ChemSpider
identifier：20400
resource：BindingDB
identifier：50144936
resource：PharmGKB
identifier：PA451876
resource：PDB
identifier：RAB
resource：Therapeutic Targets Database
identifier：DAP000642
resource：Wikipedia
identifier：Vidarabine
resource：ChEMBL
identifier：CHEMBL1090
resource：ZINC
identifier：ZINC000000970363
resource：RxCUI
identifier：11194
外部链接
RxList
http://www.rxlist.com/cgi/generic3/vidarabine.htm
Drugs.com
http://www.drugs.com/mtm/vidarabine-ophthalmic.html
目标
id:BE0000308
name:DNA polymerase catalytic subunit
organism:HHV-1
action:inhibitor
Suzuki M, Okuda T, Shiraki K: Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72(2):157-61. Epub 2006 May 30.
Sagar S, Kaur M, Minneman KP: Antiviral lead compounds from marine sponges. Mar Drugs. 2010 Oct 11;8(10):2619-38. doi: 10.3390/md8102619.
known-action:yes
name:DNA polymerase catalytic subunit
general-function:Rna-dna hybrid ribonuclease activity
specific-function:Replicates viral genomic DNA. The replication complex is composed of six viral proteins: the DNA polymerase, processivity factor, primase, primase-associated factor, helicase, and ssDNA-binding protein. Additionally, the polymerase contains an intrinsic ribonuclease H (RNase H) activity that specifically degrades RNA/DNA heteroduplexes or duplex DNA substrates in the 5' to 3' direction. Therefore, it can catalyze the excision of the RNA primers that initiate the synthesis of Okazaki fragments at a replication fork during viral DNA replication.
gene-name:
locus:
cellular-location:Host nucleus
transmembrane-regions:
signal-regions:
theoretical-pi:7.31
molecular-weight:136419.66
chromosome-location:
organism:HHV-1
external-identifiers:GenBank Gene DatabaseX14112GenBank Protein Database59530UniProtKBP04293UniProt AccessionDPOL_HHV11
synonyms:2.7.7.7
amino-acid-sequence:>lcl|BSEQ0000613|DNA polymerase catalytic subunit
MFSGGGGPLSPGGKSAARAASGFFAPAGPRGASRGPPPCLRQNFYNPYLAPVGTQQKPTG
PTQRHTYYSECDEFRFIAPRVLDEDAPPEKRAGVHDGHLKRAPKVYCGGDERDVLRVGSG
GFWPRRSRLWGGVDHAPAGFNPTVTVFHVYDILENVEHAYGMRAAQFHARFMDAITPTGT
VITLLGLTPEGHRVAVHVYGTRQYFYMNKEEVDRHLQCRAPRDLCERMAAALRESPGASF
RGISADHFEAEVVERTDVYYYETRPALFYRVYVRSGRVLSYLCDNFCPAIKKYEGGVDAT
TRFILDNPGFVTFGWYRLKPGRNNTLAQPAAPMAFGTSSDVEFNCTADNLAIEGGMSDLP
AYKLMCFDIECKAGGEDELAFPVAGHPEDLVIQISCLLYDLSTTALEHVLLFSLGSCDLP
ESHLNELAARGLPTPVVLEFDSEFEMLLAFMTLVKQYGPEFVTGYNIINFDWPFLLAKLT
DIYKVPLDGYGRMNGRGVFRVWDIGQSHFQKRSKIKVNGMVNIDMYGIITDKIKLSSYKL
NAVAEAVLKDKKKDLSYRDIPAYYAAGPAQRGVIGEYCIQDSLLVGQLFFKFLPHLELSA
VARLAGINITRTIYDGQQIRVFTCLLRLADQKGFILPDTQGRFRGAGGEAPKRPAAARED
EERPEEEGEDEDEREEGGGEREPEGARETAGRHVGYQGARVLDPTSGFHVNPVVVFDFAS
LYPSIIQAHNLCFSTLSLRADAVAHLEAGKDYLEIEVGGRRLFFVKAHVRESLLSILLRD
WLAMRKQIRSRIPQSSPEEAVLLDKQQAAIKVVCNSVYGFTGVQHGLLPCLHVAATVTTI
GREMLLATREYVHARWAAFEQLLADFPEAADMRAPGPYSMRIIYGDTDSIFVLCRGLTAA
GLTAVGDKMASHISRALFLPPIKLECEKTFTKLLLIAKKKYIGVIYGGKMLIKGVDLVRK
NNCAFINRTSRALVDLLFYDDTVSGAAAALAERPAEEWLARPLPEGLQAFGAVLVDAHRR
ITDPERDIQDFVLTAELSRHPRAYTNKRLAHLTVYYKLMARRAQVPSIKDRIPYVIVAQT
REVEETVARLAALRELDAAAPGDEPAPPAALPSPAKRPRETPSPADPPGGASKPRKLLVS
ELAEDPAYAIAHGVALNTDYYFSHLLGAACVTFKALFGNNAKITESLLKRFIPEVWHPPD
DVAARLRTAGFGAVGAGATAEETRRMLHRAFDTLA
gene-sequence:>lcl|BSEQ0021646|DNA polymerase catalytic subunit
ATGTTTTCCGGTGGCGGCGGCCCGCTGTCCCCCGGAGGAAAGTCGGCGGCCAGGGCGGCG
TCCGGGTTTTTTGCGCCCGCCGGCCCTCGCGGAGCCAGCCGGGGACCCCCGCCTTGTTTG
AGGCAAAACTTTTACAACCCCTACCTCGCCCCAGTCGGGACGCAACAGAAGCCGACCGGG
CCAACCCAGCGCCATACGTACTATAGCGAATGCGATGAATTTCGATTCATCGCCCCGCGG
GTGCTGGACGAGGATGCCCCCCCGGAGAAGCGCGCCGGGGTGCACGACGGTCACCTCAAG
CGCGCCCCCAAGGTGTACTGCGGGGGGGACGAGCGCGACGTCCTCCGCGTCGGGTCGGGC
GGCTTCTGGCCGCGGCGCTCGCGCCTGTGGGGCGGCGTGGACCACGCCCCGGCGGGGTTC
AACCCCACCGTCACCGTCTTTCACGTGTACGACATCCTGGAGAACGTGGAGCACGCGTAC
GGCATGCGCGCGGCCCAGTTCCACGCGCGGTTTATGGACGCCATCACACCGACGGGGACC
GTCATCACGCTCCTGGGCCTGACTCCGGAAGGCCACCGGGTGGCCGTTCACGTTTACGGC
ACGCGGCAGTACTTTTACATGAACAAGGAGGAGGTCGACAGGCACCTACAATGCCGCGCC
CCACGAGATCTCTGCGAGCGCATGGCCGCGGCCCTGCGCGAGTCCCCGGGCGCGTCGTTC
CGCGGCATCTCCGCGGACCACTTCGAGGCGGAGGTGGTGGAGCGCACCGACGTGTACTAC
TACGAGACGCGCCCCGCTCTGTTTTACCGCGTCTACGTCCGAAGCGGGCGCGTGCTGTCG
TACCTGTGCGACAACTTCTGCCCGGCCATCAAGAAGTACGAGGGTGGGGTCGACGCCACC
ACCCGGTTCATCCTGGACAACCCCGGGTTCGTCACCTTCGGCTGGTACCGTCTCAAACCG
GGCCGGAACAACACGCTAGCCCAGCCGCGGGCCCCGATGGCCTTCGGGACATCCAGCGAC
GTCGAGTTTAACTGTACGGCGGACAACCTGGCCATCGAGGGGGGCATGAGCGACCTACCG
GCATACAAGCTCATGTGCTTCGATATCGAATGCAAGGCGGGGGGGGAGGACGAGCTGGCC
TTTCCGGTGGCCGGGCACCCGGAGGACCTGGTCATCCAGATATCCTGTCTGCTCTACGAC
CTGTCCACCACCGCCCTGGAGCACGTCCTCCTGTTTTCGCTCGGTTCCTGCGACCTCCCC
GAATCCCACCTGAACGAGCTGGCGGCCAGGGGCCTGCCCACGCCCGTGGTTCTGGAATTC
GACAGCGAATTCGAGATGCTGTTGGCCTTCATGACCCTTGTGAAACAGTACGGCCCCGAG
TTCGTGACCGGGTACAACATCATCAACTTCGACTGGCCCTTCTTGCTGGCCAAGCTGACG
GACATTTACAAGGTCCCCCTGGACGGGTACGGCCGCATGAACGGCCGGGGCGTGTTTCGC
GTGTGGGACATAGGCCAGAGCCACTTCCAGAAGCGCAGCAAGATAAAGGTGAACGGCATG
GTGAACATCGACATGTACGGGATTATAACCGACAAGATCAAGCTCTCGAGCTACAAGCTC
AACGCCGTGGCCGAAGCCGTCCTGAAGGACAAGAAGAAGGACCTGAGCTATCGCGACATC
CCCGCCTACTACGCCGCCGGGCCCGCGCAACGCGGGGTGATCGGCGAGTACTGCATACAG
GATTCCCTGCTGGTGGGCCAGCTGTTTTTTAAGTTTTTGCCCCATCTGGAGCTCTCGGCC
GTCGCGCGCTTGGCGGGTATTAACATCACCCGCACCATCTACGACGGCCAGCAGATCCGC
GTCTTTACGTGCCTGCTGCGCCTGGCCGACCAGAAGGGCTTTATTCTGCCGGACACCCAG
GGGCGATTTAGGGGCGCCGGGGGGGAGGCGCCCAAGCGTCCGGCCGCAGCCCGGGAGGAC
GAGGAGCGGCCAGAGGAGGAGGGGGAGGACGAGGACGAACGCGAGGAGGGCGGGGGCGAG
CGGGAGCCGGAGGGCGCGCGGGAGACCGCCGGCAGGCACGTGGGGTACCAGGGGGCCAGG
GTCCTTGACCCCACTTCCGGGTTTCACGTGAACCCCGTGGTGGTGTTCGACTTTGCCAGC
CTGTACCCCAGCATCATCCAGGCCCACAACCTGTGCTTCAGCACGCTCTCCCTGAGGGCC
GACGCAGTGGCGCACCTGGAGGCGGGCAAGGACTACCTGGAGATCGAGGTGGGGGGGCGA
CGGCTGTTCTTCGTCAAGGCTCACGTGCGAGAGAGCCTCCTCAGCATCCTCCTGCGGGAC
TGGCTCGCCATGCGAAAGCAGATCCGCTCGCGGATTCCCCAGAGCAGCCCCGAGGAGGCC
GTGCTCCTGGACAAGCAGCAGGCCGCCATCAAGGTCGTGTGTAACTCGGTGTACGGGTTC
ACGGGAGTGCAGCACGGACTCCTGCCGTGCCTGCACGTTGCCGCGACGGTGACGACCATC
GGCCGCGAGATGCTGCTCGCGACCCGCGAGTACGTCCACGCGCGCTGGGCGGCCTTCGAA
CAGCTCCTGGCCGATTTCCCGGAGGCGGCCGACATGCGCGCCCCCGGGCCCTATTCCATG
CGCATCATCTACGGGGACACGGACTCCATCTTTGTGCTGTGCCGCGGCCTCACGGCCGCC
GGGCTGACGGCCGTGGGCGACAAGATGGCGAGCCACATCTCGCGCGCGCTGTTTCTGCCC
CCCATCAAACTCGAGTGCGAAAAGACGTTCACCAAGCTGCTGCTGATCGCCAAGAAAAAG
TACATCGGCGTCATCTACGGGGGTAAGATGCTCATCAAGGGCGTGGATCTGGTGCGCAAA
AACAACTGCGCGTTTATCAACCGCACCTCCAGGGCCCTGGTCGACCTGCTGTTTTACGAC
GATACCGTCTCCGGAGCGGCCGCCGCGTTAGCCGAGCGCCCCGCGGAGGAGTGGCTGGCG
CGACCCCTGCCCGAGGGACTGCAGGCGTTCGGGGCCGTCCTCGTAGACGCCCATCGGCGC
ATCACCGACCCGGAGAGGGACATCCAGGACTTTGTCCTCACCGCCGAACTGAGCAGACAC
CCGCGCGCGTACACCAACAAGCGCCTGGCCCACCTGACGGTGTATTACAAGCTCATGGCC
CGCCGCGCGCAGGTCCCGTCCATCAAGGACCGGATCCCGTACGTGATCGTGGCCCAGACC
CGCGAGGTAGAGGAGACGGTCGCGCGGCTGGCCGCCCTCCGCGAGCTAGACGCCGCCGCC
CCAGGGGACGAGCCCGCCCCCCCCGCGGCCCTGCCCTCCCCGGCCAAGCGCCCCCGGGAG
ACGCCGTCGCCTGCCGACCCCCCGGGAGGCGCGTCCAAGCCCCGCAAGCTGCTGGTGTCC
GAGCTGGCCGAGGATCCCGCATACGCCATTGCCCACGGCGTCGCCCTGAACACGGACTAT
TACTTCTCCCACCTGTTGGGGGCGGCGTGCGTGACATTCAAGGCCCTGTTTGGGAATAAC
GCCAAGATCACCGAGAGTCTGTTAAAAAGGTTTATTCCCGAAGTGTGGCACCCCCCGGAC
GACGTGGCCGCGCGGCTCCGGACCGCAGGGTTCGGGGCGGTGGGTGCCGGCGCTACGGCG
GAGGAAACTCGTCGAATGTTGCATAGAGCCTTTGATACTCTAGCATGA
pfams:PF00136DNA_pol_BPF03104DNA_pol_B_exo1PF11590DNAPolymera_Pol
go-classifiers:componenthost cell nucleusfunction3'-5' exonuclease activityfunction5'-3' exonuclease activityfunctionDNA bindingfunctionDNA-directed DNA polymerase activityfunctionnucleotide bindingfunctionRNA-DNA hybrid ribonuclease activityprocessbidirectional double-stranded viral DNA replicationprocessRNA phosphodiester bond hydrolysis, endonucleolyticprocessRNA phosphodiester bond hydrolysis, exonucleolytic
id:BE0004499
name:Thymidine kinase
organism:
action:inducer
Suzuki M, Okuda T, Shiraki K: Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72(2):157-61. Epub 2006 May 30.
Henrot A: [Mother-infant and indirect transmission of HSV infection: treatment and prevention]. Ann Dermatol Venereol. 2002 Apr;129(4 Pt 2):533-49.
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
known-action:yes
name:Thymidine kinase
general-function:Catalyzes the transfer of the gamma-phospho group of ATP to thymidine to generate dTMP in the salvage pathway of pyrimidine synthesis. The dTMP serves as a substrate for DNA polymerase during viral DNA replication. Allows the virus to be reactivated and to grow in non-proliferative cells lacking a high concentration of phosphorylated nucleic acid precursors.
specific-function:Atp binding
gene-name:TK
locus:
cellular-location:
transmembrane-regions:
signal-regions:
theoretical-pi:
molecular-weight:37816.49
chromosome-location:
organism:HHV-3
external-identifiers:UniProtKBP09250UniProt AccessionKITH_VZVD
synonyms:2.7.1.21
amino-acid-sequence:>lcl|BSEQ0017455|Thymidine kinase
MSTDKTDVKMGVLRIYLDGAYGIGKTTAAEEFLHHFAITPNRILLIGEPLSYWRNLAGED
AICGIYGTQTRRLNGDVSPEDAQRLTAHFQSLFCSPHAIMHAKISALMDTSTSDLVQVNK
EPYKIMLSDRHPIASTICFPLSRYLVGDMSPAALPGLLFTLPAEPPGTNLVVCTVSLPSH
LSRVSKRARPGETVNLPFVMVLRNVYIMLINTIIFLKTNNWHAGWNTLSFCNDVFKQKLQ
KSECIKLREVPGIEDTLFAVLKLPELCGEFGNILPLWAWGMETLSNCSRSMSPFVLSLEQ
TPQHAAQELKTLLPQMTPANMSSGAWNILKELVNAVQDNTS
gene-sequence:
pfams:PF00693Herpes_TK
go-classifiers:functionATP bindingfunctionthymidine kinase activityprocessDNA biosynthetic processprocessTMP biosynthetic process
id:BE0000458
name:Thymidine kinase
organism:HHV-1
action:inducer
Suzuki M, Okuda T, Shiraki K: Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72(2):157-61. Epub 2006 May 30.
Henrot A: [Mother-infant and indirect transmission of HSV infection: treatment and prevention]. Ann Dermatol Venereol. 2002 Apr;129(4 Pt 2):533-49.
known-action:yes
name:Thymidine kinase
general-function:Thymidine kinase activity
specific-function:In latent infection, may allow the virus to be reactivated and to grow in cells lacking a high concentration of phosphorylated nucleic acid precursors, such as nerve cells that do not replicate their genome.
gene-name:TK
locus:-
cellular-location:
transmembrane-regions:
signal-regions:
theoretical-pi:7.7
molecular-weight:40896.475
chromosome-location:
organism:HHV-1
external-identifiers:GenBank Gene DatabaseAF243477GenBank Protein Database8100965UniProtKBQ9QNF7UniProt AccessionKITH_HHV1
synonyms:2.7.1.21UL23
amino-acid-sequence:>lcl|BSEQ0010320|Thymidine kinase
MASYPCHQHASAFDQAARSRGHSNRRTALRPRRQQEATEVRLEQKMPTLLRVYIDGPHGM
GKTTTTQLLVALGSRDDIVYVPEPMTYWQVLGASETIANIYTTQHRLDQGEISAGDAAVV
MTSAQITMGMPYAVTDAVLAPHIGGEAGSSHAPPPALTLIFDRHPIAALLCYPAARYLMG
SMTPQAVLAFVALIPPTLPGTNIVLGALPEDRHIDRLAKRQRPGERLDLAMLAAIRRVYG
LLANTVRYLQGGGSWREDWGQLSGTAVPPQGAEPQSNAGPRPHIGDTLFTLFRAPELLAP
NGDLYNVFAWALDVLAKRLRPMHVFILDYDQSPAGCRDALLQLTSGMVQTHVTTPGSIPT
ICDLARTFAREMGEAN
gene-sequence:>lcl|BSEQ0000912|1131 bp
ATGGCTTCGTACCCCTGCCATCAACACGCGTCTGCGTTCGACCAGGCTGCGCGTTCTCGC
GGCCATAGCAACCGACGTACGGCGTTGCGCCCTCGCCGGCAGCAAGAAGCCACGGAAGTC
CGCCTGGAGCAGAAAATGCCCACGCTACTGCGGGTTTATATAGACGGTCCTCACGGGATG
GGGAAAACCACCACCACGCAACTGCTGGTGGCCCTGGGTTCGCGCGACGATATCGTCTAC
GTACCCGAGCCGATGACTTACTGGCAGGTGCTGGGGGCTTCCGAGACAATCGCGAACATC
TACACCACACAACACCGCCTCGACCAGGGTGAGATATCGGCCGGGGACGCGGCGGTGGTA
ATGACAAGCGCCCAGATAACAATGGGCATGCCTTATGCCGTGACCGACGCCGTTCTGGCT
CCTCATATCGGGGGGGAGGCTGGGAGCTCACATGCCCCGCCCCCGGCCCTCACCCTCATC
TTCGACCGCCATCCCATCGCCGCCCTCCTGTGCTACCCGGCCGCGCGATACCTTATGGGC
AGCATGACCCCCCAGGCCGTGCTGGCGTTCGTGGCCCTCATCCCGCCGACCTTGCCCGGC
ACAAACATCGTGTTGGGGGCCCTTCCGGAGGACAGACACATCGACCGCCTGGCCAAACGC
CAGCGCCCCGGCGAGCGGCTTGACCTGGCTATGCTGGCCGCGATTCGCCGCGTTTACGGG
CTGCTTGCCAATACGGTGCGGTATCTGCAGGGCGGCGGGTCGTGGCGGGAGGATTGGGGA
CAGCTTTCGGGGACGGCCGTGCCGCCCCAGGGTGCCGAGCCCCAGAGCAACGCGGGCCCA
CGACCCCATATCGGGGACACGTTATTTACCCTGTTTCGGGCCCCCGAGTTGCTGGCCCCC
AACGGCGACCTGTATAACGTGTTTGCCTGGGCCTTGGACGTCTTGGCCAAACGCCTCCGT
CCCATGCACGTCTTTATCCTGGATTACGACCAATCGCCCGCCGGCTGCCGGGACGCCCTG
CTGCAACTTACCTCCGGGATGGTCCAGACCCACGTCACCACCCCAGGCTCCATACCGACG
ATCTGCGACCTGGCGCGCACGTTTGCCCGGGAGATGGGGGAGGCTAACTGA
pfams:PF00693Herpes_TK
go-classifiers:functionATP bindingfunctionthymidine kinase activityprocessDNA biosynthetic processprocessTMP biosynthetic process
酶
BE0002214Adenosine deaminaseHumanssubstrateA150436980706Agarwal RP, Blatt J, Miser J, Sallan S, Lipton JM, Reaman GH, Holcenberg J, Poplack DG: Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin. Cancer Res. 1982 Sep;42(9):3884-6.A150442538128Balzarini J, De Clercq E: The antiviral activity of 9-beta-D-arabinofuranosyladenine is enhanced by the 2',3'-dideoxyriboside, the 2',3'-didehydro-2',3'-dideoxyriboside and the 3'-azido-2',3'-dideoxyriboside of 2,6-diaminopurine. Biochem Biophys Res Commun. 1989 Feb 28;159(1):61-7.A150453339608Cristalli G, Franchetti P, Grifantini M, Vittori S, Lupidi G, Riva F, Bordoni T, Geroni C, Verini MA: Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. J Med Chem. 1988 Feb;31(2):390-3.unknownAdenosine deaminaseZinc ion bindingCatalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion.ADA20q12-q13.11Cell membrane5.840764.1320HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:186GenAtlasADAGenBank Gene DatabaseX02994GenBank Protein Database28380Guide to Pharmacology1230UniProtKBP00813UniProt AccessionADA_HUMAN3.5.4.4ADA1Adenosine aminohydrolase>lcl|BSEQ0020603|Adenosine deaminase
MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPD
FLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQA
EGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAI
DLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGY
HTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIF
KSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAG
QNL>lcl|BSEQ0020604|Adenosine deaminase (ADA)
ATGGCCCAGACGCCCGCCTTCGACAAGCCCAAAGTAGAACTGCATGTCCACCTAGACGGA
TCCATCAAGCCTGAAACCATCTTATACTATGGCAGGAGGAGAGGGATCGCCCTCCCAGCT
AACACAGCAGAGGGGCTGCTGAACGTCATTGGCATGGACAAGCCGCTCACCCTTCCAGAC
TTCCTGGCCAAGTTTGACTACTACATGCCTGCTATCGCGGGCTGCCGGGAGGCTATCAAA
AGGATCGCCTATGAGTTTGTAGAGATGAAGGCCAAAGAGGGCGTGGTGTATGTGGAGGTG
CGGTACAGTCCGCACCTGCTGGCCAACTCCAAAGTGGAGCCAATCCCCTGGAACCAGGCT
GAAGGGGACCTCACCCCAGACGAGGTGGTGGCCCTAGTGGGCCAGGGCCTGCAGGAGGGG
GAGCGAGACTTCGGGGTCAAGGCCCGGTCCATCCTGTGCTGCATGCGCCACCAGCCCAAC
TGGTCCCCCAAGGTGGTGGAGCTGTGTAAGAAGTACCAGCAGCAGACCGTGGTAGCCATT
GACCTGGCTGGAGATGAGACCATCCCAGGAAGCAGCCTCTTGCCTGGACATGTCCAGGCC
TACCAGGAGGCTGTGAAGAGCGGCATTCACCGTACTGTCCACGCCGGGGAGGTGGGCTCG
GCCGAAGTAGTAAAAGAGGCTGTGGACATACTCAAGACAGAGCGGCTGGGACACGGCTAC
CACACCCTGGAAGACCAGGCCCTTTATAACAGGCTGCGGCAGGAAAACATGCACTTCGAG
ATCTGCCCCTGGTCCAGCTACCTCACTGGTGCCTGGAAGCCGGACACGGAGCATGCAGTC
ATTCGGCTCAAAAATGACCAGGCTAACTACTCGCTCAACACAGATGACCCGCTCATCTTC
AAGTCCACCCTGGACACTGATTACCAGATGACCAAACGGGACATGGGCTTTACTGAAGAG
GAGTTTAAAAGGCTGAACATCAATGCGGCCAAATCTAGTTTCCTCCCAGAAGATGAAAAG
AGGGAGCTTCTCGACCTGCTCTATAAAGCCTATGGGATGCCACCTTCAGCCTCTGCAGGG
CAGAACCTCTGAPF00962A_deaminasecomponentcell junctioncomponentcell surfacecomponentcytoplasmcomponentcytoplasmic membrane-bounded vesicle lumencomponentcytosolcomponentdendrite cytoplasmcomponentexternal side of plasma membranecomponentextracellular spacecomponentlysosomecomponentmembranecomponentneuronal cell bodycomponentplasma membranefunctionadenosine deaminase activityfunctionpurine nucleoside bindingfunctionzinc ion bindingprocessadenosine catabolic processprocessagingprocessdATP catabolic processprocessdeoxyadenosine catabolic processprocessembryonic digestive tract developmentprocessgerminal center B cell differentiationprocesshistamine secretionprocesshypoxanthine salvageprocessinosine biosynthetic processprocessliver developmentprocesslung alveolus developmentprocessnegative regulation of adenosine receptor signaling pathwayprocessnegative regulation of circadian sleep/wake cycle, non-REM sleepprocessnegative regulation of inflammatory responseprocessnegative regulation of leukocyte migrationprocessnegative regulation of mature B cell apoptotic processprocessnegative regulation of mucus secretionprocessnegative regulation of penile erectionprocessnegative regulation of thymocyte apoptotic processprocessnucleobase-containing small molecule metabolic processprocessPeyer's patch developmentprocessplacenta developmentprocesspositive regulation of alpha-beta T cell differentiationprocesspositive regulation of B cell proliferationprocesspositive regulation of calcium-mediated signalingprocesspositive regulation of germinal center formationprocesspositive regulation of heart rateprocesspositive regulation of smooth muscle contractionprocesspositive regulation of T cell differentiation in thymusprocesspositive regulation of T cell receptor signaling pathwayprocesspurine nucleobase metabolic processprocesspurine nucleotide salvageprocesspurine ribonucleoside monophosphate biosynthetic processprocesspurine-containing compound salvageprocessregulation of cell-cell adhesion mediated by integrinprocessresponse to drugprocessresponse to hydrogen peroxideprocessresponse to hypoxiaprocessresponse to morphineprocessresponse to vitamin Eprocesssmall molecule metabolic processprocessT cell activationprocesstrophectodermal cell differentiationprocessxanthine biosynthetic process